Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 4/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743043 | 0.93 | CTSK (0.49) | CTSKCTSLCTSSCASP1CASP3 | |
| SCHEMBL5741577 | 0.92 | CTSK (0.48) | CTSKCTSLCTSSCASP1CASP3 | |
| SCHEMBL5742583 | 0.91 | CTSK (0.49) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL5743932 | 0.91 | CTSK (0.53) | CTSKCTSLCTSS | |
| SCHEMBL5744045 | 0.90 | CTSK (0.59) | CTSKCTSLCTSSCTSB | |
| SCHEMBL5744857 | 0.90 | CTSK (0.59) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6512679 | 0.89 | CTSK (0.53) | CTSK | |
| SCHEMBL5745249 | 0.88 | CTSK (0.56) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6517727 | 0.86 | CTSK (0.51) | CTSK | |
| SCHEMBL6513944 | 0.85 | CTSK (0.50) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | CTSK 4/4885KAT6A 3503/4885CTSL 10/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | CTSK 5/4885KAT6A 2854/4885CTSL 13/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | CTSK 3/4885KAT6A 3339/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.